Diabetes Management and Cardiovascular Risk: Are SGLT-2 Inhibitors the Safest?

Metabolic Syndrome and Related Disorders

Volumn 14, Issue 1, 2016, Pages 3-6

  Swislocki, Arthur L M ^a,b   Jialal, Ishwarlal ^a,b  

^a VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALOGLIPTIN; DULAGLUTIDE; EMPAGLIFLOZIN; EXENDIN 4; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INCRETIN; INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PHENFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

AWARENESS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG SAFETY; FRACTURE; GENITAL TRACT INFECTION; HEART FAILURE; HUMAN; HYPOGLYCEMIA; KETOACIDOSIS; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RISK ASSESSMENT; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84955105270     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2015.29003.swi     Document Type: Review

References (32)

1. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972;21:976-979.
2. Feinstein AR. Clinical biostatistics. XXXV. The persistent clinical failures and fallacies of the UGDP study. Clin Pharmacol Ther 1976;19:78-93.
3. Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the UGDP. Am Heart J 1999;138: S346-S52.
4. Riveline JP, Danchin N, Ledru F, et al. Sulfonylureas and cardiovascular effects: From experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 2003;29:207-222.
5. Meier JJ, Gallwitz B, Schmidt WE, et al. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004;90:9-12. Review.
6. Bolen S, Feldman L, Vassy J, et al. Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147: 386-399.
7. Khalaf KI, Taegtmeyer H. After Avandia: The use of antidiabetic drugs in patients with heart failure. Tex Heart Inst J 2012;39:174-178.
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471.
9. Starner CI, Schafer JA, Heaton AH, et al. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm 2008;14:523-531.
10. Pouwels KB, van Grootheest K. The rosiglitazone decision process at FDA and EMA. What should we learn? Int J Risk Saf Med 2012;24:73-80.
11. Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study. Circulation 2005;111:583-590.
12. Florez H, Reaven PD, Bahn G, et al.; VADT Research Group. Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial. Diabetes Obes Metab 2015;17:949-955.
13. Eurich DT, Majumdar SR, McAlister FA, et al. Levels of evidence needed for changing indications, contraindications, and Food and Drug Administration labeling: The case of metformin. Arch Intern Med 2011;171:1042-1043.
14. Roussel R, Travert F, Pasquet B, et al.; Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010; 170:1892-1899.
15. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in patients in overweight patients with T2DM. (UKPDS-34). Lancet1998:352;854-865.
16. Hong J, Zhang Y, Lai S, et al.; SPREAD-DIMCAD Investigators. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013;36:1304-1311.
17. Kao J, Tobis J, McClelland RL, et al. Investigators in the Prevention of Restenosis With Tranilast and Its Outcomes Trial. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 2004;93:1347-1350, A5.
18. Chang CH, Chang YC, Lin JW, et al. Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: A nationwide cohort study. J Clin Endocrinol Metab 2015;100:1121-1129.
19. Chen JM, Chang CW, Lin YC, et al. Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: A nationwide seven-year follow-up study. J Diabetes Res 2014;2014:812628.
20. Chiasson JL, Josse RG, Gomis R, et al.; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003;290:486-494.
21. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: Diabetes Mellitus- evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Accessed at www.fda.gov/downloads/ drugs/guidancecomplianceregulatoryinformation/guidances/ ucm071627.pdf on October 14, 2015.
22. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326.
23. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369: 1327-1335.
24. Jialal I, Dhindsa S. No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: Potential explanations. Metab Syndr Relat Dis 2014;12:157-158.
25. Green JB, Bethel A, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type2 diabetes. N Eng J Med 2015;373:232-242.
26. Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension 2014;64: 731-737.
27. Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J 2015;36:2288-2296.
28. Rotz ME, Ganetsky VS, Sen S, et al. Implications of incretin-based therapies on cardiovascular disease. Int J Clin Pract 2015;69:531-549.
29. Sun F,Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res Clin Pract 2015;110:26-37.
30. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; [Epub ahead of print] DOI 10.1056/nejmoa1504720
31. Swislocki AL, Jialal I. The novel role of the kidney in diabetes management: Sodium-Glucose Co-Transporter 2 Inhibitors. Metab Syndr Relat Disord 2015;13:287-291.
32. Ford ES. Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: Findings from the National Health and Nutrition Examination Survey, 1999-2008. Diabetes Care 2011;34:1337-1343.